Hodgkin's Lymphoma In Low-Income Countries: Experience Of Togo

Author:

Padaro Essohana1,Womey Kodzovi M C1,Layibo Yao2,Adandodo Kadara R1,Magnang Hèzouwè1,Kueviakoe Mensah D I3

Affiliation:

1. Hematology Department, Campus University Hospital Center, University of Lomé, Togo

2. Hematology Laboratory, Sylvanus Olympio University Hospital Center, University of Lomé, Togo

3. Hematology Laboratory, Tsévié Regional Hospital Center, University of Lomé, Togo

Abstract

While highly curable in developed countries, Hodgkin's lymphoma (HL), remains a significant challenge for resource-limited ones. This study aimed to describe the profile of HL in Togo. This was a retrospective, descriptive study conducted at the Clinical Hematology Department of the Campus University Hospital Center in Lomé, Togo. It focused on patient records diagnosed with HL between January 1, 2006, and December 31, 2022. Various variables such as age, gender, histological type of HL, Ann Arbor stage, prognostic classification, therapeutic protocol used, and patient outcomes were examined. The annual incidence of HL was 1.5 with a mean age of 38.7 years (range 12-63). Lymph node enlargement was the primary clinical sign (100%). Histologically, classical HL was found in 21 patients (87.5%). Staging was conducted for 16 (66.7%) patients, among whom 11 (66.7%) were at an advanced stage, and 6 (37.5%) had an unfavorable prognosis. The ABVD protocol was used in 13 patients (54.2%), receiving between 1 and 6 cycles. One patient achieved complete remission (4.1%), three deceased (12.5%), and 17 (71%) were lost to follow-up. Hodgkin's lymphoma prognosis remains unfavorable with low remission rates in Togo. Improving the technical facilities will ensure better management of this lymphoma.

Publisher

Open Access Pub

Reference31 articles.

1. 1.Wang H-W, Balakrishna J P, Pittaluga S, Jaffe E S. (2019) Diagnosis of Hodgkin lymphoma in the modern era. , Br 184-45.

2. 2.Weniger M A, Küppers R.Molecular biology of Hodgkin lymphoma. , Leukemia 35(9), 68-81.

3. 3.Swerdlow S H, Campo E, Pileri S A, Harris N L, Stein H et al. (2016) revision of the World Health Organization classification of lymphoid neoplasms. , Blood 127(23), 75-90.

4. 4.Alaggio R, Amador C, Anagnostopoulos I, Attygalle A D, O Araujo IB de et al. (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia.

5. 5.Howlader N, Noone A M, Krapcho M, Garshell J, Miller D et al. (2023) . SEER cancer statistics review, 1975–2012. Natl Cancer Inst [Internet]. 2014; [cité 21 Disponible sur: https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3420543 .

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3